Kaizen Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Kaizen Advisory's VRTX Position: Q4 2018 in Review
Kaizen Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 15% in Q4 2018, buying an estimated $15.9K and bringing the position to 693 shares worth $115K. The position accounts for 0.08% of the portfolio, ranked #208.
Kaizen Advisory first reported a position in VRTX in Q4 2017 and has held it in 5 quarters since. The position peaked at $116K in Q3 2018. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.
- Kaizen Advisory held 693 shares of Vertex Pharmaceuticals worth $115K as of Q4 2018.
- Kaizen Advisory bought 92 Vertex Pharmaceuticals shares in Q4 2018, an estimated $15.9K.
- Vertex Pharmaceuticals made up 0.08% of Kaizen Advisory's portfolio in Q4 2018, its #208 holding.
- Kaizen Advisory first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
- Kaizen Advisory's Vertex Pharmaceuticals position peaked at $116K in Q3 2018.
- 705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.
Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.